Marching Toward Progress (Jun 17, 2019 - Jun 17, 2020)

Marching Toward Progress is organized by prIME Oncology. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

Target Audience:
This educational activity is designed to meet the needs of medical, surgical, and radiation oncologists, as well as advanced practitioners and midlevel providers, who treat/manage patients with lung cancer in the VA system or in the VA choice programs.

Learning Objectives:
After successful completion of this educational activity, participants should be able to:
• Understand key components of the immune system and the biochemistry associated with checkpoint blockade, including specific inhibitors of PD-1/PD-L1 and CTLA-4
• Implement effective strategies for integrating checkpoint inhibitors into the treatment of non-small cell lung cancer (NSCLC)
• Develop treatment plans to manage both common and rare immune-related adverse events (irAEs) associated with the use of checkpoint inhibitors in lung cancer

Additional details will be posted as soon as they are available.